EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Broncus Holding's Enterprise Value is HK$-665.70 Mil.
Broncus Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-155.63 Mil. Therefore, Broncus Holding's EV-to-FCF for today is 4.28.
The historical rank and industry rank for Broncus Holding's EV-to-FCF or its related term are showing as below:
HKSE:02216'
s EV-to-FCF Range Over the Past 10 Years
Min: -59.81 Med: 3.97 Max: 4.97
Current: 4.78
During the past 5 years, the highest EV-to-FCF of Broncus Holding was 4.97. The lowest was -59.81. And the median was 3.97.
HKSE:02216's EV-to-FCF is ranked better than 90.89% of 384
companies
in the Medical Devices & Instruments industry
Industry Median: 26.5
vs HKSE:02216: 4.78
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Broncus Holding's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Broncus Holding's EV-to-FCF
For the Medical Devices subindustry, Broncus Holding's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Broncus Holding's EV-to-FCF falls into.
Broncus Holding's current Enterprise Value is HK$-665.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Broncus Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-155.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Broncus Holding's PE Ratio (TTM) for today is calculated as:
Broncus Holding's share price for today is HK$0.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Broncus Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Broncus Holding EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Broncus Holding's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02216 has been successfully added to your 